COMMUNIQUÉS West-GlobeNewswire

HighLife Receives CE Mark Approval for Clarity Valve, the Next-Generation Valve for the HighLife TMVR System
27/08/2026
Paris, France - August 27, 2026 – HighLife SAS, a medical technology company focused on the development of a unique transcatheter mitral valve replacement (“TMVR”) system to treat patients suffering from mitral [...]
Orion Corporation to commence acquisition of own shares for its share-based incentive plans
27/08/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 27 AUGUST 2026 at 13.00 EEST Orion Corporation to commence acquisition of own shares for its share-based [...]
Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference
27/08/2026
DEER PARK, Ill., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]
HighLife Receives CE Mark Approval for Clarity Valve, the Next-Generation Valve for the HighLife TMVR System
27/08/2026
Paris, France - August 27, 2026 – HighLife SAS, a medical technology company focused on the development of a unique transcatheter mitral valve replacement (“TMVR”) system to treat patients suffering from mitral [...]
IBA publie ses résultats semestriels 2026, et confirme sa trajectoire d’amélioration de la rentabilité
27/08/2026
Louvain-La-Neuve, Belgique, 27 août 2026, 7h00 - IBA (Ion Beam Applications S.A.), annonce aujourd’hui ses résultats consolidés pour le premier semestre 2026, avec une performance conforme aux prévisions pour l’exercice [...]
IBA reports Half Year 2026 results, on track with its improved profitability trajectory
27/08/2026
Louvain-la-Neuve, Belgium, 27 August 2026, 7 a.m. - IBA (Ion Beam Applications S.A.), today announces its consolidated results for the first half of 2026, with performance on track with FY 2026 guidance and continued [...]
Nicox annonce avril 2027 comme date PDUFA pour NCX 470 dans le traitement du glaucome
27/08/2026
Communiqué de presse Nicox annonce avril 2027 comme date PDUFA pour NCX 470 dans le traitement du glaucome La FDA a fixé la date de réponse à l’examen de la NDA dans le cadre du Prescription Drug User Fee Act (PDUFA) au [...]
Nicox Announces April 2027 PDUFA Date for NCX 470 in Glaucoma
27/08/2026
Press Release Nicox Announces April 2027 PDUFA Date for NCX 470 in Glaucoma FDA sets Prescription Drug User Fee Act (PDUFA) review response date by 30 April 2027 Two NDAs filed in major markets, with commercial partners [...]
A decade of profitability provides foundation for CLINUVEL’s U.S. expansion
27/08/2026
MELBOURNE, Australia and NEW YORK, Aug. 27, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced its tenth consecutive annual profit and further rise in free cash in the [...]
hVIVO acquires CRS Berlin, expanding expertise into dermatology and women's health markets
27/08/2026
London, UK – 27 August 2026 , hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announces the acquisition of CRS Clinical [...]
Osivax and GC Biopharma Enter Strategic Collaboration to Develop a Next-Generation Influenza Vaccine Combining OVX836 and GC FLU
27/08/2026
Combines Osivax's proprietary OVX836 T-cell vaccine and technology with GC Biopharma's marketed influenza vaccine and worldwide manufacturing expertise Positions Osivax as the global development lead for a [...]
Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates
27/08/2026
SHANGHAI, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
Mesoblast Reports Substantial Revenue Growth to US$120M
27/08/2026
RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment Financial Results and Operational Update for Full Year Ended June 30, 2026 NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: [...]
Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026
26/08/2026
Six presentations planned, including encore oral presentation of topline X-TOLE2 efficacy and safety results New poster will highlight the mechanistic characterization of azetukalner, including its potential additive [...]
Interpace Biosciences Announces Reverse Stock Split to Support Proposed Nasdaq Uplisting
26/08/2026
PARSIPPANY, NJ, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCID: IDXG) (“Interpace” or the “Company”), an emerging leader in enabling personalized medicine, today announced that it will effect a 1- [...]
Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology
26/08/2026
European Patent Office granted Vaxart a new patent, extending intellectual property protection for Vaxart’s Norovirus vaccine program through at least 2036 across key European markets KEY HIGHLIGHTS: • European Patent [...]
First Tracks Biotherapeutics Announces Participation in September Investor Conferences
26/08/2026
SAN DIEGO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in [...]
RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference
26/08/2026
ALISO VIEJO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, [...]
Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
26/08/2026
- For patients with second-line (2L) metastatic pancreatic cancer, today’s FDA approval of a new treatment is an important milestone – - For patients with first-line (1L) metastatic pancreatic cancer, Immuneering’s [...]

Pages